A gene test may help predict survival in glioblastoma
Original title: Transcriptomic Features Predict Survival in Glioblastoma Patients.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was a computer study of stored data, not a test or treatment people can get.
The short version
Researchers used gene activity in stored tumor samples to sort patients into higher and lower risk groups.
What was studied. Researchers used stored data from 518 glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary tumor samples. They looked at 12,042 gene features and how long patients lived. A computer method picked out the genes tied to survival.
What they found. The computer model kept 74 genes. Two of them, called CLEC5A and RANBP17, had also shown up in an earlier study. The model split patients into a higher risk group and a lower risk group. That split held up in a separate set of 104 patients the model had not seen.
What this means, and what it doesn't
What it could mean: This is early work on a possible way to guess how a tumor may behave. In time, tests like this might help doctors know who needs closer watching. It does not change how glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary is treated today.
What it doesn't mean: This is not a treatment, and it is not a cure. It is a computer study of data that was already collected. No one was given a new drug or a new therapy. The model was only fair at telling people apart, not exact. It has not been tested in the clinic, and no doctor can order this test for you now.
Source: PubMed, July 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.